Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial    save search
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLK
Published: 2023-12-03 (Crawled : 00:00) - prnewswire.com
AHCO | $8.83 4.13% -0.11% 790K twitter stocktwits trandingview |
Finance
 | Email alert Add to watchlist
OTLK | $0.4728 -1.5% -1.84% 1.6M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
SLRN | News | $6.88 2.38% -2.04% 990K twitter stocktwits trandingview |
| Email alert Add to watchlist
deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages NuScale Power Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - SMR
Published: 2023-12-03 (Crawled : 20:20) - prnewswire.com
GDHG | News | $20.55 -4.77% 1.22% 340K twitter stocktwits trandingview |
| Email alert Add to watchlist
PAYC | News | $185.75 2.25% -0.03% 1.3M twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
corporation deadline trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Published: 2023-12-03 (Crawled : 20:20) - prnewswire.com
SLRN | News | $6.88 2.38% -2.04% 990K twitter stocktwits trandingview |
| Email alert Add to watchlist
FTCH | News | $1.28 9.4% 0.78% 32M twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
deadline trial
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Published: 2023-12-01 (Crawled : 18:00) - globenewswire.com
CMND | $4.14 18.29% 2.63% 11M twitter stocktwits trandingview |
n/a
 | | O: 21.29% H: 0.0% C: 0.0%
SPRC | $7.96 1.92% 0.5% 530K twitter stocktwits trandingview |
Manufacturing
 | | O: -0.75% H: 0.0% C: 0.0%
obesity drug pre-clinical positive trial results
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Published: 2023-12-01 (Crawled : 17:00) - globenewswire.com
CMND | $4.14 18.29% 2.63% 11M twitter stocktwits trandingview |
n/a
 | | O: 21.29% H: 0.0% C: 0.0%
obesity drug pre-clinical positive trial results
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
TOT | $48.3 0% twitter stocktwits trandingview |
Energy Minerals
 | Email alert Add to watchlist
nrtx-1001 cell ongoing trial therapeutics therapy
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
PHGE | $0.258 -0.39% 0.0% 370K twitter stocktwits trandingview |
Health Technology
 | | O: -19.28% H: 0.0% C: 0.0%
bx004 review positive fibrosis infections trial results
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
ALT | $3.57 12.98% 3.36% 100M twitter stocktwits trandingview |
Commercial Services
 | | O: 4.47% H: 0.0% C: 0.0%
obesity momentum positive topline trial results
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
CDXC | $1.41 1.44% -0.71% 110K twitter stocktwits trandingview |
Process Industries
 | | O: 4.51% H: 2.16% C: 0.0%
niagen trial milestone
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
NLTX | $3.5 1.16% 0.0% 35K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ngn-401 treatment trial
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
BNTC | $3.22 1.26% 1.86% 11K twitter stocktwits trandingview |
Health Technology
 | | O: 0.63% H: 8.29% C: -0.63%
bb-301 candidate treatment biopharma trial therapy
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
SNGX | $0.73 75.73% -5.49% 7M twitter stocktwits trandingview |
Health Technology
 | | O: 32.76% H: 0.0% C: 0.0%
fda disease treatment clearance trial
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
TARA | $1.435 -1.03% -1.05% 20K twitter stocktwits trandingview |
Health Technology
 | | O: -2.01% H: 4.71% C: -0.68%
tara-002 presentation meeting trial therapeutics
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
ABBV | $143.41 0.72% -0.11% 4.9M twitter stocktwits trandingview |
Health Technology
 | | O: -0.73% H: 0.78% C: 0.35%
lung abbvie positive cancer cell topline trial results
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
Published: 2023-11-29 (Crawled : 14:00) - globenewswire.com
SLS | $1.08 3.85% 0.83% 480K twitter stocktwits trandingview |
Health Technology
 | | O: -1.87% H: 24.76% C: 0.0%
life sciences leukemia trial
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Published: 2023-11-29 (Crawled : 13:30) - globenewswire.com
DYAI | $1.77 4.73% 0.0% 48K twitter stocktwits trandingview |
Health Technology
 | | O: -0.85% H: 5.71% C: -2.29%
candidate vaccine trial results
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
TSHA | $1.84 4.55% -2.72% 1.6M twitter stocktwits trandingview |
Health Technology
 | | O: 3.43% H: 3.87% C: 0.55%
reveal trial
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
BIVI P | $1.68 -6.67% 4.17% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: -70.4% H: 0.0% C: 0.0%
ne3107 disease alzheimer’s trial
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
PBLA | $0.5987 12.96% -11.69% 350K twitter stocktwits trandingview |
Professional, Scientific, and T...
 | | O: 21.33% H: 0.0% C: 0.0%
continuation review aspire trial
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
Published: 2023-11-29 (Crawled : 12:30) - globenewswire.com
SABS | $0.94 -3.29% 4.26% 250K twitter stocktwits trandingview |
| | O: 0.44% H: 2.22% C: -3.33%
sab-142 trial diabetes potential
Gainers vs Losers
77% 23%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.